Celgene Corporation Elects John Weiland to Its Board of Directors

SUMMIT, N.J.–()–Celgene Corporation (NASDAQ: CELG) today announced the election of John
Weiland to its Board of Directors. Mr. Weiland has over 30 years in the
healthcare industry and was most recently the President and Chief
Operating Officer of C. R. Bard, Inc. (Bard), with worldwide
responsibility for all of Bard’s business operations prior to it being
acquired by Becton, Dickinson and Company (BD) in December 2017.

Mr. Weiland joined Bard in 1996. Prior to becoming President and COO,
Mr. Weiland held the position of Group President of Bard and had global
responsibility for Bard Medical Division, Bard Urological Division,
Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide
Manufacturing Operations. In addition, Mr. Weiland also had
responsibility for Bard’s businesses in Latin America, Mexico, Canada,
the Far East and Japan. Mr. Weiland served as a director of Bard since
2005 and prior to it being acquired by BD.

Mr. Weiland started his career at Baxter/American Hospital Supply
Corporation in 1977. He rose through numerous managerial positions
including Vice President and General Manager of the Scientific Products
Biomedical Division, Vice President and General Manager of Baxter
International – Scientific Products Division, and Vice President East
American Scientific Products Division of Baxter Healthcare Corp. In
1989, he became President and Chief Executive Officer of Pharmacia
Diagnostics, Inc., a division of Pharmacia AB Upsala Sweden. In 1991, he
was named Senior Vice President North America Group for Dentsply
International, the world’s leading dental products manufacturer. He
holds a B.S. from DeSales University and earned an M.B.A. from New York
University.

In addition to his professional activities, Mr. Weiland is actively
involved in civic affairs. In 1987, he was named a White House Fellow
and served as a Special Assistant to President Reagan’s Cabinet. Mr.
Weiland is a 2012 recipient of the prestigious Horatio Alger Award. He
serves as a director of the Horatio Alger Association, the National
Committee for Quality Health Care (NCQHC), Meridian Health System and
West Pharmaceutical Services. He also served as a member of the Board of
Trustees of DeSales University for nineteen years.

“John is an accomplished leader in the healthcare industry with
significant expertise and experience across therapeutic areas and
geographies,” said Mark Alles, Chairman and CEO of Celgene Corporation.
“His leadership and insight will help to inform and direct Celgene’s
long-term growth strategy.”

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene,
Pinterest,
LinkedIn,
Facebook
and YouTube.

Hyperlinks are provided as a convenience and for informational purposes
only. Celgene bears no responsibility for the security or content of
external websites.

Forward-Looking Statement

This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words “expects,” “anticipates,”
“believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Exchange Commission.





Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: